Loading…
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $330M | $39M | $19M | $40M | 8.7% | 12.5% | 12.5% |
| 2024 | $293M | $32M | $17M | $38M | 7.8% | 6.8% | -40.5% |
| 2023 | $274M | $26M | $29M | $33M | 14.7% | 11.2% | - |
| 2022 | $247M | $2M | $-18M | $3M | -14.7% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 246.78 | 274.42 | 292.98 | 329.52 |
| Cost Of Revenue | 70.81 | 79.29 | 76.30 | 79.38 |
| Gross Profit | 175.98 | 195.13 | 216.69 | 250.15 |
| Operating Expense | 188.73 | 177.09 | 194.51 | 220.87 |
| Operating Income | -12.76 | 18.04 | 22.18 | 29.28 |
| EBITDA | 1.75 | 26.46 | 32.37 | 39.02 |
| EBIT | -12.69 | 19.92 | 25.57 | 32.38 |
| Pretax Income | -15.47 | 15.77 | 23.49 | 31.34 |
| Tax Provision | 2.39 | -12.74 | 6.53 | 12.25 |
| Net Income | -17.87 | 28.52 | 16.96 | 19.09 |
| Net Income Common Stockholders | -17.87 | 28.52 | 16.96 | 19.09 |
| Total Expenses | 259.54 | 256.38 | 270.80 | 300.24 |
| Interest Expense | 2.79 | 4.15 | 2.08 | 1.04 |
| Interest Income | 0.06 | 1.87 | 3.38 | 3.10 |
| Research And Development | 7.09 | 7.82 | 8.83 | 8.48 |
| Selling General And Administration | 167.21 | 169.19 | 183.14 | 209.94 |
| Normalized EBITDA | 1.75 | 26.46 | 32.37 | 39.02 |
| Normalized Income | -17.87 | 28.52 | 16.96 | 19.09 |
| Basic EPS | -0.89 | 1.24 | 0.71 | 0.83 |
| Diluted EPS | -0.89 | 1.23 | 0.70 | 0.82 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.28 | 0.39 |
| Net Income From Continuing Operation Net Minority Interest | -17.87 | 28.52 | 16.96 | 19.09 |
| Reconciled Depreciation | 6.27 | 6.54 | 6.79 | 6.64 |
| Reconciled Cost Of Revenue | 78.97 | 72.83 | 72.03 | 75.18 |
| Net Interest Income | -2.73 | -2.27 | 1.30 | 2.06 |
| Net Income From Continuing And Discontinued Operation | -17.87 | 28.52 | 16.96 | 19.09 |
| Rent Expense Supplemental | 11.19 | 12.58 | 11.48 | 10.69 |
| Total Operating Income As Reported | -12.76 | 18.04 | 22.18 | 29.28 |
| Diluted Average Shares | 20.07 | 23.18 | 24.14 | 23.30 |
| Basic Average Shares | 20.07 | 22.93 | 23.88 | 22.87 |
| Diluted NI Availto Com Stockholders | -17.87 | 28.52 | 16.96 | 19.09 |
| Net Income Including Noncontrolling Interests | -17.87 | 28.52 | 16.96 | 19.09 |
| Net Income Continuous Operations | -17.87 | 28.52 | 16.96 | 19.09 |
| Other Income Expense | 0.01 | 0 | 0.01 | 0 |
| Other Non Operating Income Expenses | 0.01 | 0 | 0.01 | 0 |
| Net Non Operating Interest Income Expense | -2.73 | -2.27 | 1.30 | 2.06 |
| Interest Expense Non Operating | 2.79 | 4.15 | 2.08 | 1.04 |
| Interest Income Non Operating | 0.06 | 1.87 | 3.38 | 3.10 |
| Depreciation Amortization Depletion Income Statement | 14.43 | 0.08 | 2.53 | 2.44 |
| Depreciation And Amortization In Income Statement | 14.43 | 0.08 | 2.53 | 2.44 |
| Amortization | 14.43 | 0.08 | 2.53 | 2.44 |
| Amortization Of Intangibles Income Statement | 14.43 | 0.08 | 2.53 | 2.44 |
| Selling And Marketing Expense | 106.42 | 107.12 | 112.01 | 121.24 |
| General And Administrative Expense | 60.80 | 62.07 | 71.14 | 88.70 |
| Other Gand A | 60.80 | 62.07 | 71.14 | 88.70 |
| Operating Revenue | 246.78 | 274.42 | 292.98 | 329.52 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Tactile Systems Technology, Inc.this co. | TCMD | $512M | 27.44 | 2.31 | 8.7% | 12.18 |
| SI-BONE, Inc. | SIBN | $528M | - | 2.93 | -10.6% | -25.11 |
| Personalis, Inc. | PSNL | $528M | - | 1.98 | -31.1% | -4.25 |
| Altimmune, Inc. | ALT | $511M | - | 1.30 | -39.2% | -1.10 |
| Tectonic Therapeutic, Inc. | TECX | $510M |
| - |
| 2.02 |
| -29.5% |
| -3.09 |
| Aquestive Therapeutics, Inc. | AQST | $503M | - | -14.67 | 248.9% | -5.90 |
| XOMA Royalty Corporation | XOMA | $497M | 28.08 | 5.79 | 37.8% | 38.75 |
| Entrada Therapeutics, Inc. | TRDA | $494M | - | 1.50 | -47.0% | -1.40 |
| Esperion Therapeutics, Inc. | ESPR | $492M | - | -1.55 | 7.5% | 14.42 |
| Peer Median | - | 28.08 | 1.74 | -20.1% | -2.25 | |